Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIGHT: Ranibizumab for Diabetic Macular Edema
NCT01257815Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Apr 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Change in Mean Best Corrected Visual Acuity at 12 months. Started Jan 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01257815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257815.